AstraZeneca doesn’t quite know why its diabetes drug Farxiga is also working in patients with heart failure – but what it does know is that, if approved in this new use on this basis, it co
The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney
AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabe
Novo Nordisk is facing a lawsuit from disgruntled investors seeking around $1.8 billion in compensation, saying the company failed to properly update the market about the situation regardin
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
